TICKERNERD
Menu
TVGNTVGNHealthcare · Biotechnology

TVGN Stock Forecast: Tevogen, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$6.49
−1.67% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 6 Oct 2026 — in the weakest quartile.

Market cap
$45.5M
Ticker Nerd rank
16 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$5.7M
Net income−$5.8M
Free cash flow−$3.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
−11.6%
YTD
−60.8%
1Y
−80.0%
From 52W high
−82.8%
From 52W low
+66.8%
$4
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TVGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tevogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
83
Growth
60
Value
51
Accruals
49
Revisions
25
Volatility
15
Quality
11
Momentum
8
Issuance
6

Size (83): Smaller than most of the companies we track.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TVGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TVGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26TVGN

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Mar 2026D. Boral CapitalDowngradeHold—
3 Mar 2026D. Boral CapitalMaintainsBuy$5.00 → $2.00
20 Nov 2025D. Boral CapitalMaintainsBuy—
4 Sept 2025D. Boral CapitalMaintainsBuy—
18 Aug 2025D. Boral CapitalMaintainsBuy—
6 Aug 2025D. Boral CapitalMaintainsBuy—
4 Aug 2025D. Boral CapitalMaintainsBuy—
18 June 2025D. Boral CapitalMaintainsBuy—
10 June 2025D. Boral CapitalMaintainsBuy—
27 May 2025D. Boral CapitalMaintainsBuy—
12 May 2025D. Boral CapitalMaintainsBuy—
29 Apr 2025D. Boral CapitalMaintainsBuy—
21 Apr 2025D. Boral CapitalMaintainsBuy—
11 Mar 2025D. Boral CapitalMaintainsBuy—
4 Mar 2025D. Boral CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TVGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TVGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Tevogen, Inc. returned −80.0% against +17.3% for the S&P 500, dividends included.

TVGN vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26TVGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TVGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Tevogen, Inc. (TVGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.9×

Cheaper than 68% of US stocks

Price / sales
—
Price / book
−3.0×

Cheaper than 96% of US stocks

EV / EBITDA
−2.9×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
319.1%

Higher than 99% of US stocks

Return on assets
−297.4%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tevogen, Inc. (TVGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tevogen, Inc. has a market value of $45.5M and an enterprise value of $62.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$21.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$11.6M.

  • Shares outstanding: 4.2M.

  • Trailing P/E: 2.9×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tevogen, Inc. employs 18 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

TVGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TVGNTevogen, Inc.$45.5M
16
VERUVeru, Inc.$42.1M
61
FLNAFilana Therapeutics, Inc.$42.3M
66
LITSLite Strategy, Inc.$42.9M
33
IBOImpact BioMedical, Inc.$40.0M
24
BSEMBioStem Technologies, Inc.$44.0M
57
HOWLWerewolf Therapeutics, Inc.$44.7M
84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tevogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TVGN news & analysis

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

GlobeNewsWire · 30 Sept 2026positive

Tevogen announced that it received written notice from Nasdaq on September 29, 2026, confirming the company has regained compliance with the $50 million minimum market value of listed securities requirement under Nasdaq Listing Rule 5450(B)(2)(A) for continued listing on the Nasdaq Global Market.

Why it matters — Regaining compliance removes the immediate risk of delisting and secures Tevogen's continued listing on the Nasdaq Global Market.

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

GlobeNewsWire · 29 July 2026neutral

Tevogen Bio Holdings Inc. announced it will change its corporate name to Tevogen Inc., following approval by its Board of Directors. The company will operate under the new name effective immediately.

Why it matters — A name change can signal a shift in corporate identity or strategy, and shareholders will need to be aware of the new legal name for filings and communications.

FAQ

Frequently asked questions about TVGN stock

Is TVGN stock a buy right now?

Of the 1 analysts covering Tevogen, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tevogen, Inc. 16 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TVGN?

As at 6 Oct 2026, Tevogen, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).

What is the TVGN stock forecast for 2030?

No analyst covering Tevogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TVGN are extrapolating price history, which says nothing about the business.

How has TVGN stock performed over the past year?

Tevogen, Inc. returned -80.0% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tevogen, Inc. do?

Tevogen Inc. Common Stock is the equity security of Tevogen Inc., a clinical-stage specialty immunotherapy company focused on off-the-shelf precision T cell therapies.

What is the latest news on TVGN?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements". Tevogen announced that it received written notice from Nasdaq on September 29, 2026, confirming the company has regained compliance with the $50 million minimum market value of listed securities requirement under Nasdaq Listing Rule 5450(B)(2)(A) for continued listing on the Nasdaq Global Market.

Company

About Tevogen, Inc.

Tevogen Inc. Common Stock is the equity security of Tevogen Inc., a clinical-stage specialty immunotherapy company focused on off-the-shelf precision T cell therapies. The company develops treatments for infectious diseases, cancers, and other serious disorders, with current programs centered on viral infections, virus-related complications, and selected oncology and immune-related indications. Its platform combines cell therapy development with artificial intelligence tools that support drug discovery and therapeutic design. Tevogen’s pipeline includes product candidates in clinical and preclinical stages, reflecting a research-driven biotechnology business model centered on advancing targeted therapies. Headquartered in Warren, New Jersey, Tevogen Inc. operates as part of the broader healthcare and biotechnology market, where it contributes to the development of scalable immunotherapy solutions for unmet medical needs.

CEO Dr. Ryan H. Saadi M.D., M.P.H. · 18 employees · United States · https://tevogen.com